Hong Kong Exchanges and Clearing Limited (HKEX) disclosures from August 28 indicate that Frontera Therapeutics has submitted a fresh listing application for the Main Board, with UBS Group and Haitong International acting as joint sponsors. This marks the company's second attempt, following an initial filing on December 23, 2025.

Established in 2019, Frontera Therapeutics is a clinical-stage gene therapy company dedicated to developing proprietary recombinant adeno-associated virus (rAAV) gene therapies, with a pipeline particularly concentrated on ophthalmology and cardiovascular diseases. As of the latest practicable date, the company's pipeline encompasses six internally developed rAAV gene therapy drug candidates. These include two core products: FT-002, being studied for X-linked retinitis pigmentosa; and FT-003, an investigational candidate for treating neovascular age-related macular degeneration and diabetic macular edema via intravitreal injection. Additionally, the pipeline features one key product, FT-001, a gene therapy candidate for inherited retinal diseases linked to biallelic RPE65 gene mutations, alongside three other preclinical and early-stage gene therapy candidates targeting ophthalmic and cardiovascular indications.

Frontera Therapeutics cites several competitive strengths: a differentiated gene therapy pipeline with leading clinical progress in China; AAVANCE, its Bac/Sf9-based production platform designed for safe, scalable, and cost-effective high-quality manufacturing; robust translational medicine and clinical operational capabilities leveraging its footprint in both China and the United States; an rAAV gene therapy R&D platform supported by globally protected intellectual property; and deep gene therapy expertise across research, translational, clinical, and manufacturing disciplines. The company has assembled an internal R&D team of 37 members based in China and the US as of June 30, 2026, with more than 56% holding doctoral or master's degrees in fields such as medicine, biology, pharmacology, and chemistry. The average industry experience of its R&D team surpasses ten years, with strong records in advancing gene therapy drug development.

As of the latest practicable date, Frontera Therapeutics has not obtained marketing approval for any drug candidate and has not generated any revenue from product sales.

Financial data shows that R&D expenses for fiscal years ended December 31, 2024, and 2025 stood at $20.6 million and $13.9 million, accounting for 74.6% and 73.1% of total operating expenses, respectively. For the six-month periods ended June 30, 2025, and June 30, 2026, R&D expenses were $7.1 million and $5.3 million, representing 72.4% and 68.6% of total operating expenses, respectively. During these periods, expenses incurred in the US were recorded at $8.4 million in FY2024, $5.1 million in FY2025, and $1.1 million in the first half of 2026, together accounting for approximately 36.5% of total R&D spending across the track record period. Net losses amounted to $26.5 million and $19.5 million for the 2024 and 2025 fiscal years, narrowing to $8.2 million and $4.7 million for the respective first-half periods ended June 30, 2025, and 2026. The decrease in net losses primarily reflects lower R&D expenditure.

The global gene therapy market achieved a valuation of $3.6 billion in 2025, following an extraordinary growth phase from 2020 to 2025 at a compound annual growth rate of 226.6%. Projections indicate the market will expand at 28.1% annually from 2025 to 2030, reaching $12.5 billion by 2030, with further growth anticipated to $32 billion by 2035 at a CAGR of 20.8% between 2030 and 2035. China's gene therapy market, currently in its nascent stages with a total size of approximately RMB 40 million in 2025, is expected to rocketing at a CAGR of 143.8% through 2030 to RMB 3.2 billion, and then reaching RMB 22.8 billion by 2035 at a CAGR of 90.1% from 2030 to 2035.

AAV is a single-stranded DNA virus characterized by inverted terminal repeat (ITR) sequences at both ends of its genome DNA, which are essential for DNA replication initiation and packaging of recombinant AAV particles. Between these ITRs resides the viral coding region containing two genes: Rep, primarily responsible for replication of the viral genome and its integration into the host genome, and Cap, which mediates packaging of the viral genome and its secretion from host cells.

As of the latest practicable date, over 250 rAAV gene therapy drugs are in development worldwide, with five under BLA phase evaluation. Development remains concentrated in early-stage clinical trials, with approximately 53% of candidates in Phase I/II trials assessing safety, initial efficacy, and dose exploration. Independent Phase I studies account for another 27%, reflecting a steady influx of first-in-human candidates. Late-stage activity is emerging, with Phase III projects making up 10% of the pipeline, Phase II 6%, and Phase II/III 3%.

Rare diseases and ophthalmic conditions dominate the global rAAV gene therapy pipeline, with rare disease treatments comprising over half of all investigational rAAV products. In terms of therapeutic areas, ophthalmic diseases represent the most targeted field, followed by neuromuscular, cardiovascular, and hematological conditions. In recent years, rAAV gene therapy has emerged as a promising treatment approach for several ophthalmic diseases, particularly fundus neovascular disorders, offering key advantages over alternative treatments and addressing substantial unmet medical needs.

The global ophthalmic drug market has grown steadily over the past five years, expanding from $33.5 billion in 2020 to $44.1 billion in 2025 at a CAGR of 5.7%. It is projected to approach $49.4 billion by 2030 and reach $65.5 billion by 2035, reflecting CAGRs of 2.3% (2025-2030) and 5.8% (2030-2035). Currently, no rAAV-based gene therapy products have been approved for the same indications as the company's core candidates.

The board of directors at Frontera Therapeutics includes nine members: one executive director, five non-executive directors, and three independent non-executive directors. Under the company's articles of association, directors serve three-year terms and are eligible for re-election, with the board holding general authority to manage the company's business affairs.

Equity structure reveals that OrbiMed Asia Partners III, L.P. is managed by OrbiMed Asia GP III, L.P., whose general partner is OrbiMed Advisors III Limited, while OrbiMed Private Investments VII, LP is managed by OrbiMed Capital GP VII LLC, whose managing member is OrbiMed Advisors LLC. OrbiMed Advisors LLC serves as the advisor to OrbiMed Asia with voting rights under their advisory agreement and holds controlling voting power over OrbiMed US, thereby jointly controlling both entities.

The intermediary team is composed of UBS Securities Hong Kong Limited and Haitong International Capital Limited as joint sponsors; Skadden, Arps, Slate, Meagher & Flom LLP and affiliates, Wilson Sonsini Goodrich & Rosati, Zhong Lun Law Firm, and Harneys as company legal counsel; Herbert Smith Freehills and Global Law Office as joint sponsor legal counsel; Deloitte Touche Tohmatsu as reporting accountant and auditor; and Frost & Sullivan (Beijing) Co., Ltd. Shanghai Branch as industry consultant.